

required by the 1990 amendment of section 8 of the Clayton Act. Section 8 prohibits, with certain exceptions, one person from serving as a director or officer of two competing corporations if two thresholds are met. Competitor corporations are covered by section 8 if each one has capital, surplus, and undivided profits aggregating more than \$10,000,000, with the exception that no corporation is covered if the competitive sales of either corporation are less than \$1,000,000. Section 8(a)(5) requires the Federal Trade Commission to revise those thresholds annually, based on the change in gross national product. The new thresholds, which take effect immediately, are \$12,804,000 for section 8(a)(1), and \$1,280,400 for section 8(a)(2)(A).

**EFFECTIVE DATE:** January 18, 1995.

**FOR FURTHER INFORMATION CONTACT:** James Mongoven, Bureau of Competition, Office of Policy and Evaluation, (202) 326-2879.

**Authority:** 15 U.S.C. 19(a)(5).

By direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 95-1154 Filed 1-17-95; 8:45 am]

**BILLING CODE 6750-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Meetings

Pursuant to Public Law 92-463, notice is hereby given of meetings of the National Institute of Neurological Disorders and Stroke (NINDS).

The National Advisory Neurological Disorders and Stroke Council and its subcommittee meetings will be open to the public as indicated below. Attendance by the public will be limited to space available.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92-463, for the review, discussion and evaluation of individual grant applications. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of meetings, rosters of committee members, and other information pertaining to the meetings can be obtained from the Executive Secretary or the Scientific Review Administrator indicated. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary listed for the meeting.

**Name of Committee:** The Planning Subcommittee of the National Advisory Neurological Disorders and Stroke Council.

**Date:** February 15, 1995.

**Place:** National Institutes of Health, Building 32, Conference Room 8A28, 9000 Rockville Pike, Bethesda, MD 20892.

**Open:** 1:30 p.m.-3 p.m.

**Agenda:** To discuss program planning and fiscal matters.

**Closed:** 3 p.m.—recess.

**Name of Committee:** National Advisory Neurological Disorders and Stroke Council.

**Date:** February 16-17, 1995.

**Place:** National Institutes of Health, Building 1, Wilson Hall, 9000 Rockville Pike, Bethesda, MD 20892.

**Open:** February 16, 9 a.m.-1 p.m.

**Agenda:** A report by the Director, NINDS, a report by the Acting Director, Division of Extramural Activities, NINDS, a scientific presentation by an NINDS intramural scientist and a presentation by the Director of the National Center for Human Genome Research.

**Closed:** February 16, 1 p.m.—recess;

February 17, 8:30 a.m.—adjournment.

**Executive Secretary:** Constance W. Atwell, Ph.D., Acting Director, Division of Extramural Activities, NINDS, National Institutes of Health, Bethesda, MD 20892, Telephone: (301) 496-9248.

The following meetings will be totally closed to review and evaluate grant applications:

**Name of Committee:** Neurological Disorders Program Project Review B. Committee.

**Date:** February 8-9, 1995.

**Time:** February 8, 7:30 a.m.—recess;

February 9, 7:30 a.m.—adjournment.

**Place:** Miyako Hotel, 1625 Post Street, San Francisco, CA 94115.

**Contact Person:** Dr. Paul Sheehy, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C10, Bethesda, MD 20892, (301) 496-9223.

**Name of Committee:** Neurological Disorders Program Project Review A Committee.

**Date:** February 12-14, 1995.

**Time:** February 12, 1 p.m.—recess; February 13, 8:30 a.m.—recess; February 14, 8:30 a.m.—adjournment.

**Place:** Hawthorn Suites Hotel, 181 Church Street, Charleston, SC 29401.

**Contact Person:** Dr. Katherine Woodbury, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C14, Bethesda, MD 20892, (301) 496-9223.

**Name of Committee:** Training Grant and Career Development Review Committee.

**Date:** March 2-3, 1995.

**Time:** March 2, 8 p.m.—recess; March 3, 8 a.m.—adjournment.

**Place:** Hyatt Regency, One Bethesda Metro Center, Bethesda, MD 20892.

**Contact Person:** Dr. Alfred Gordon, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C14, Bethesda, MD 20892, (301) 496-9223. (Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

**Dated:** January 11, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-1092 Filed 1-17-95; 8:45 am]

**BILLING CODE 4140-01-M**

#### Ad Hoc Review Committee for the Recombinant DNA Advisory Committee; Notice of Meeting

Notice is given of a meeting of the Ad Hoc Review Committee for the Recombinant DNA Advisory Committee on February 3, 1995, at the National Institutes of Health, Building 31, 9000 Rockville Pike, Bethesda, Maryland 20892. The meeting will be held from approximately 9 a.m. to 12 noon in Room 2C15, and continue in Room 5A16 from approximately 12 noon to adjournment at approximately 5 p.m. The meeting will be open to the public to discuss three major topics for review: (1) Domain and mandate of the Recombinant DNA Advisory Committee; (2) composition of the Recombinant DNA Advisory Committee; and (3) Recombinant DNA Advisory Committee's review of human gene transfer protocols. Members of the public wishing to speak at this meeting may be given such opportunity at the discretion of the Chair.

Dr. Nelson A. Wivel, Director, Office of Recombinant DNA Activities, Suite 323, National Institutes of Health, 6006 Executive Boulevard, MSC 7052, Bethesda, Maryland 20892-7052, Phone (301) 496-9838, FAX (301) 496-9839, will provide materials to be discussed at this meeting, roster of committee members, and substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Wivel in advance of the meeting. A summary of the meeting will be available at a later date.